Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
PepGen Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"At-The-Market Equity Offering Sales Agreement by and between the Company and Stifel, Nicolaus & Company, Incorporated",
"Opinion of Goodwin Procter LLP"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months EndedJune 30, 2023 2022 Operating expenses: Research and development $ 16,926 $ 14,240 General and administrative 4,218 3,401 Total operating expenses $ 21,144 $ 17,641 Operating loss $ $ Other income Interest income 1,684 250 Other income , net 76 Total other income , net 1,622 326 Net loss before income tax $ $ Income tax expense - - Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,790,430 14,090,455 Condensed Consolidated Balance Sheets June 30,2023"
06/09/2023 4 McArthur James G (President and CEO) has filed a Form 4 on PepGen Inc.
Txns: Sold 2,381 shares @ $16.0386, valued at $38.2k
Exercised 2,381 options to buy @ $2.71, valued at $6.5k
06/08/2023 4 McArthur James G (President and CEO) has filed a Form 4 on PepGen Inc.
Txns: Sold 18,150 shares @ $16.1796, valued at $293.7k
Sold 8,419 shares @ $16.2273, valued at $136.6k
Exercised 18,150 options to buy @ $2.71, valued at $49.2k
Exercised 8,419 options to buy @ $2.71, valued at $22.8k
06/06/2023 4 McArthur James G (President and CEO) has filed a Form 4 on PepGen Inc.
Txns: Sold 1,800 shares @ $16.035, valued at $28.9k
Sold 500 shares @ $16.056, valued at $8k
Exercised 1,800 options to buy @ $2.71, valued at $4.9k
Exercised 500 options to buy @ $2.71, valued at $1.4k
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months EndedMarch 31, 2023 2022 Operating expenses: Research and development $ 14,360 $ 10,707 General and administrative 3,671 3,186 Total operating expenses $ 18,031 $ 13,893 Operating loss $ $ Other income Interest income $ 1,792 $ 9 Other income , net 58 Total other income , net $ 1,712 $ 67 Net loss before income tax $ $ Income tax expense — Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,761,915 963,588 Condensed Consolidated Balance Sheets March 31,2023"
03/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 8-K Quarterly results
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Twelve Months Ended December 31, Three Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 54,077 $ 18,999 $ 13,166 $ 4,541 General and administrative 14,224 8,110 4,047 2,670 Total operating expenses $ 68,301 $ 27,109 $ 17,213 $ 7,211 Operating loss $ $ $ $ Other income Interest income 2,793 — 1,591 — Other income , net 110 67 Total other income , net 2,903 1,563 67 Net loss before income tax $ $ $ $ Income tax expense — 714 — Net loss $ $ $ $ Condensed Consolidated Balance Sheets December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 181,752 $ 132,895 Other receivables 58 4,744 Prepaid expenses and other current assets 4,273 2,347 Total current assets $ 186,083 $ 139,..."
03/22/2023 8-K Quarterly results
03/02/2023 4 Mellion Michelle L (SVP, Clinical Development) has filed a Form 4 on PepGen Inc.
Txns: Granted 75,000 options to buy @ $15.25, valued at $1.1M
Granted 20,000 options to buy @ $15.25, valued at $305k
03/02/2023 4 Goyal Jaya (EVP, Res. & Preclin. Dev.) has filed a Form 4 on PepGen Inc.
Txns: Granted 75,000 options to buy @ $15.25, valued at $1.1M
03/02/2023 4 Svenstrup Niels (SVP, Chem. Mfg & Controls) has filed a Form 4 on PepGen Inc.
Txns: Granted 75,000 options to buy @ $15.25, valued at $1.1M
03/02/2023 4 McArthur James G (President and CEO) has filed a Form 4 on PepGen Inc.
Txns: Granted 275,000 options to buy @ $15.25, valued at $4.2M
03/02/2023 4 Donnelly Noel (CFO) has filed a Form 4 on PepGen Inc.
Txns: Granted 144,000 options to buy @ $15.25, valued at $2.2M
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 6.5% stake in PepGen Inc.
02/10/2023 SC 13G/A FMR LLC reports a 10.9% stake in PEPGEN INC
02/09/2023 SC 13G FMR LLC reports a 9.3% stake in PEPGEN INC
02/08/2023 4 Goyal Jaya (EVP, Res. & Preclin. Dev.) has filed a Form 4 on PepGen Inc.
Txns: Sold 1,677 shares @ $17.035, valued at $28.6k
Sold 3,679 shares @ $17.182, valued at $63.2k
Sold 644 shares @ $17, valued at $10.9k
Exercised 1,677 options to buy @ $10.88, valued at $18.2k
Exercised 3,679 options to buy @ $10.88, valued at $40k
Exercised 644 options to buy @ $10.88, valued at $7k
01/19/2023 4 KEATING LAURIE (Director) has filed a Form 4 on PepGen Inc.
Txns: Bought 4,166 shares @ $12, valued at $50k
01/17/2023 SC 13G/A Qatar Investment Authority reports a 5.3% stake in PEPGEN INC.
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact Laurence Watts Gilmartin Group"
10/03/2022 4 Dable Habib J (Director) has filed a Form 4 on PepGen Inc.
Txns: Granted 22,686 options to buy @ $9.31, valued at $211.2k
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact Laurence Watts Gilmartin Group [email protected]",
"PHASE 1 TRIAL OF PGN-EDO51 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY"
09/22/2022 3 Dable Habib J (Director) has filed a Form 3 on PepGen Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy